Why is Adaptive Biotechnologies Corp. ?
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -80.46 MM
- NET SALES(Q) Highest at USD 58.88 MM
- RAW MATERIAL COST(Y) Fallen by -32.22% (YoY)
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Along with generating 264.16% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
How much should you buy?
- Overall Portfolio exposure to Adaptive Biotechnologies Corp. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Adaptive Biotechnologies Corp. for you?
High Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at USD -80.46 MM
Highest at USD 58.88 MM
Fallen by -32.22% (YoY
Highest at 7.46 times
Highest at USD -20.53 MM
Highest at -34.87 %
Highest at USD -25.59 MM
Highest at USD -25.61 MM
Highest at USD -0.17
Highest at 11.16 %
Lowest at USD 391.3 MM
Here's what is working for Adaptive Biotechnologies Corp.
Operating Cash Flows (USD MM)
Net Sales (USD MM)
Net Sales (USD MM)
Operating Profit (USD MM)
Operating Profit to Sales
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
EPS (USD)
Inventory Turnover Ratio
Raw Material Cost as a percentage of Sales
Here's what is not working for Adaptive Biotechnologies Corp.
Debt-Equity Ratio
Cash and Cash Equivalents






